Frontier mental health research: psychedelics & drug studies

Key findings

• Reviews identified clinical trials that tested ketamine in people with anxiety disorders and reported reduced anxiety symptoms. ¹⁵⁰⁶⁸
• In some studies, patients’ anxiety improved for several weeks after ketamine or similar psychedelic‑assisted treatments. ^{15068 15086}
• Animal studies show ketamine acts fast to reduce anxiety‑like behaviors and works mainly on the brain’s glutamate system by changing AMPA receptors and related molecules, which can boost brain plasticity (the brain’s ability to change). ^{10148 15091}
• When scientists pooled human studies that measured blood BDNF (a protein linked to brain change), they found no clear rise after psychoplastogen drugs, including ketamine, so blood BDNF is an uncertain marker of ketamine’s effects in people. ¹⁵¹²⁹
• Overall, the clinical evidence is limited: many trials are small or early‑stage, so bigger and better‑designed studies are needed before firm conclusions can be drawn. ^{15068 15091 15085}
• Reported side effects in psychedelic‑assisted studies are often mild to moderate and short‑lived, but safety monitoring remains important and dissociative drugs like ketamine can carry risks. ^{15055 15085 15099}
• Researchers stress that how the drug is given matters: preparing people beforehand, providing a safe setting, and offering follow‑up therapy are common parts of treatment and may shape outcomes. ^{15065 15096 15086}
• It is still unclear how much benefit comes from ketamine itself versus the therapy, support, and the treatment setting; separating drug effects from these psychological and contextual factors needs more study. ^{15087 15063 15085}